Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of “Buy” from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $47.00.

Several research analysts recently issued reports on the company. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 21st. Truist Financial upped their price objective on shares of Collegium Pharmaceutical from $45.00 to $48.00 and gave the company a “buy” rating in a report on Friday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. HC Wainwright boosted their target price on shares of Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Barclays initiated coverage on shares of Collegium Pharmaceutical in a research note on Monday, December 8th. They set an “overweight” rating and a $58.00 price target on the stock.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the transaction, the executive vice president directly owned 103,613 shares of the company’s stock, valued at $4,991,038.21. This represents a 14.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Rita J. Balice-Gordon sold 3,650 shares of Collegium Pharmaceutical stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director directly owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. This represents a 6.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 51,250 shares of company stock valued at $2,235,352 in the last ninety days. Company insiders own 2.51% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the business. Federated Hermes Inc. boosted its position in Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 350 shares during the last quarter. CWM LLC lifted its stake in Collegium Pharmaceutical by 453.9% in the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 1,153 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in shares of Collegium Pharmaceutical by 137.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 2,190 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Collegium Pharmaceutical by 368.9% in the second quarter. GAMMA Investing LLC now owns 2,757 shares of the specialty pharmaceutical company’s stock valued at $82,000 after purchasing an additional 2,169 shares in the last quarter.

Collegium Pharmaceutical Trading Down 0.6%

NASDAQ COLL opened at $48.71 on Wednesday. Collegium Pharmaceutical has a 52 week low of $23.23 and a 52 week high of $49.49. The company has a 50 day moving average price of $41.31 and a 200 day moving average price of $36.30. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71. The firm has a market cap of $1.54 billion, a PE ratio of 30.25 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The business had revenue of $135.55 million for the quarter. As a group, sell-side analysts forecast that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.